Premium
New Quinolines as Potential CNS Agents
Author(s) -
Sathi Garima,
Gujrati Vibha R.,
Sharma Manju,
Nath Chandishwar,
Bhargava Krishna P.,
Shanker Kirpa
Publication year - 1983
Publication title -
archiv der pharmazie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 61
eISSN - 1521-4184
pISSN - 0365-6233
DOI - 10.1002/ardp.19833160908
Subject(s) - monoamine oxidase , chemistry , in vivo , antidepressant , inhibitory postsynaptic potential , acute toxicity , pharmacology , aryl , in vitro , stereochemistry , structure–activity relationship , monoamine oxidase b , toxicity , chemical synthesis , biochemistry , enzyme , organic chemistry , biology , alkyl , neuroscience , hippocampus , microbiology and biotechnology
The compounds 1a—1l and 2a—2m were synthesized by condensation of various aryl‐1‐(4‐aminophenyl)piperazines and substituted piperidines with substituted 4‐chloroquinolines. The compounds were screened for their monoamine oxidase (MAO) inhibitory activities (in vitro) and various CNS activities (in vivo). Some compounds showed promising MAO inhibitory and antidepressant activities. The compounds did not produce acute neurological deficits and have low toxicity. Compound 1b is the most active member of the series. Structure‐activity relationships are discussed.